Genesis Mikti Idiotiki Kliniki Gynaikas A.E. Maieutiki Gynaikologiki Cheirourgiki
- Address
- 17th Noemvri Street, Pylaia, 555 35 Thessaloniki, Greece
Oncology Clinical Research
The department conducts cutting‑edge studies in neoplasms, focusing on advanced solid tumours.
- Evaluation of new immunotherapy combos
- Assessment of targeted kinase inhibitors
- Exploration of biomarker‑driven patient selection
- Comparative effectiveness of standard versus experimental regimens
- Real‑world outcome monitoring
Located at 17th Noemvri Street, Pylaia, Thessaloniki, Greece, the centre has 6 active trials led by 3 investigators.
ALK‑Positive Lung Cancer Trials
Researchers are testing next‑generation inhibitors in patients with ALK‑positive non‑small cell lung cancer.
- Head‑to‑head comparison with existing ALK drugs
- Evaluation of progression‑free survival
- Safety profiling in treatment‑naïve patients
- Combination strategies with chemotherapy
- Biomarker analysis for resistance mechanisms
The study aims to improve outcomes for a molecularly defined subgroup of lung cancer.
Melanoma Immunotherapy Research
A phase‑3 study investigates the addition of a novel agent to pembrolizumab for resected melanoma.
- Relapse‑free survival endpoint
- Assessment of overall survival benefit
- Monitoring of immune‑related adverse events
- Quality‑of‑life evaluations
- Correlative studies on tumor infiltrating lymphocytes
This trial reflects the site’s commitment to advancing immune‑based treatments for skin cancer.
HER2‑Mutated Lung Cancer Studies
The centre evaluates a targeted therapy for patients with HER2‑mutated non‑small cell lung cancer.
- Comparison with standard of care
- Objective response rate measurement
- Safety and tolerability assessment
- Molecular profiling of responders
- Exploration of combination with chemotherapy
Findings will inform personalized treatment options for a rare driver mutation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Amgen Inc.1active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Genesis Mikti Idiotiki Kliniki Gynaikas A.E. Maieutiki Gynaikologiki Cheirourgiki
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2022-08-18 | 2026-07-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.